On April 17, 2023, Interactive Capital Partners Corporation announced its intent to undertake a reverse takeover transaction with SkinJect, Inc., aiming to list on the TSX Venture Exchange. Upon completion, SkinJect will operate as a subsidiary of the company, which will be renamed "Medicus Pharma." Shareholders of SkinJect and participants of the Concurrent Financing will acquire a significant equity interest in Medicus Pharma. SkinJect, based in Pittsburgh, specializes in pharmaceutical treatments, particularly a unique treatment for non-melanoma skin cancers. Their innovative patch, designed to eliminate skin cancer, received Investigational New Drug approval from the FDA in 2018. Post approval, SkinJect successfully concluded a Phase 1 trial and is gearing up for a Phase 2 study involving 60-100 patients. In line with the Proposed Business Combination, a private placement of subscription receipts aims to raise at least US$6 million, dubbed the "Concurrent Financing". This financing attributes a pre-money value of US$25 million to SkinJect. Notably, "President's List" investors have shown interest, amounting to nearly US$3 million. The Proposed Business Combination follows a business agreement between SkinJect and Rbx on March 17, 2023. Its completion is contingent on various conditions, including regulatory consents, TSXV approvals, and the successful conclusion of the Concurrent Financing. The board for Medicus Pharma is expected to feature industry stalwarts like Dr. Larry Kaiser, Robert J. Ciaruffoli, and Dr. Raza Bokhari, with Ms. Maryann Adesso as Chief of Staff. For the transaction, Bennett Jones LLP will provide Canadian legal counsel, while Capstone Merchant Partners Inc. serves as the financial advisor.